Citations

Clear

387 citation(s) found for "Couch, Fergus".

Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer.
Foster, Nathan R. , Zhu, Mojun , Hartgers, Mindy L., Jones, Kayla M. , Bartusiewicz, Jacqueline M., Markovic, Svetomir, Ahn, Daniel H. , McWilliams, Robert R. , Kasi, Pashtoon Murtaza , Carr, Ryan M , Wee, Wen , Dong, Haidong , Markovic, Svetomir N. , Alberts, Steven R. , Babiker, Hani M. , Bekaii‐Saab, Tanios , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | January 24, 2023 | Volume: 41 | Issue: 4_suppl | Pages: TPS780-TPS780

10.1200/jco.2023.41.4_suppl.tps780 Get It

TPS780 Background: Pancreatic adenocarcinoma is an aggressive malignancy with a limited number of therapeutic options. One subset of patients (up to 15%) carries germline and/or somatic mutations in homologous recombination repair genes, most notably BRCA1, BRCA2 and PALB2 amongst others, that confer sensitivity to PARP inhibition. Combinations of PARP inhibitors with anti-PD1 immunotherapy have shown activity in breast and ovarian cancer and have not yet been thoroughly studied in pancreatic cancer. Methods: We designed a single-arm phase 2 investigator-initiated study utilizing the combination of niraparib, a highly selective PARP inhibitor and a dostarlimab, an anti PD1 antibody, in the subset of pancreatic cancer patients with germline or somatic mutations in BRCA1/2, PALB2, BARD1, RAD51C, or RAD51D. Additional inclusion criteria include metastatic pancreatic adenocarcinoma, receipt of a platinum agent in 1st or 2nd line unless contraindicated, and at least 1 but not more than 2 prior lines of systemic therapy not including maintenance. Prior PARP inhibition is allowed, but not immediately prior to enrollment. Exclusion criteria include active unstable autoimmune disease or prior malignancy requiring active treatment within 2 years. Patients are treated with niraparib 200 mg orally once daily on days 1 through 21 of a 21 day cycle. Dostarlimab is administered IV 500 mg every 3 weeks for the 1st 4 cycles and then 1000 mg IV every 6 weeks subsequently. The primary endpoint of the study is the disease control rate at 12 weeks using standard iRECIST criteria. Twenty patients will be enrolled to ensure 19 evaluable. The design has 80% power to detected improvement in disease control rate from 25-50% with significance level of 0.10. Descriptive factors include gene mutated for inclusion, germline/somatic, and platinum refractoriness. Given the size of the study along with genetic heterogeneity there will be no interim analysis. Patients are being enrolled at 3 Mayo clinic sites in Rochester Minnesota, Phoenix Arizona, Jacksonville Florida. To date, 13 patients have been enrolled across all 3 sites. Full accrual is anticipated by early 2023. Correlative studies include genomic characterization of baseline tumors, assessment of immune infiltration of tumor microenvironment, tumor collection for organoid/xenograft, and serial circulating cell-free DNA and immune biomarkers. Trial Identifiers: NCT04493060, Mayo: MC1841. Supported by Glaxo Smith Kline. Clinical trial information: NCT04493060 .
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 ,
Yadav, Siddhartha , Boddicker, Nicholas , Na, Jie , Polley, Eric C. , Hart, Steven N. , Larson, Nicole L. , Holtegaard, Susan, Huang, Huaizhi , Dunn, Carolyn, Patel, Alpa V. , Martínez, Elena, Haiman, Christopher A. , Chen, Fei , Ruddy, Kathryn J. , John, Esther M. , Kurian, Allison W. , Taylor, Jack A. , Zirpoli, Gary , Goldgar, David E. , Weitzel, Jeffrey N. , Nathanson, Katherine L. , Chen, Chen , Lumby, Carolyn A. , Boddicker, Nicholas J , Hu, Chunling , Hart, Steven N , Gnanaolivu, Rohan D., Larson, Nicole , Dunn, Carolyn A, Teras, Lauren R , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Haiman, Christopher A , Chen, Fei , Ruddy, Kathryn J , John, Esther M , Kurian, Allison W , Sandler, Dale P , O'Brien, Katie M , Taylor, Jack A , Anton-Culver, Hoda , Ziogas, Argyrios , Zirpoli, Gary , Goldgar, David E , Palmer, Julie R , Domchek, Susan M , Weitzel, Jeffrey N , Nathanson, Katherine L , Kraft, Peter , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Polley, Eric C , Na, Jie , Huang, Huaizhi , Lumby, Carolyn A , Hu, Chunling , Gnanaolivu, Rohan , Teras, Lauren R. , Lacey, James V. , Olson, Janet E. , Sandler, Dale P. , O’Brien, Katie M. , Weinberg, Clarice R. , Anton‐Culver, Hoda , Ziogas, Argyrios , Palmer, Julie R. , Domchek, Susan M. , Kraft, Peter , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2023 | Volume: 41 | Issue: 9 | Pages: 1703-1713

10.1200/jco.22.01239 | PMID 36623243 Get It

PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2. METHODS The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status. RESULTS Germline BRCA1, BRCA2, and CHEK2 PV carriers with breast cancer were at significantly elevated risk (hazard ratio > 1.9) of CBC, whereas only the PALB2 PV carriers with ER-negative breast cancer had elevated risks (hazard ratio, 2.9). By contrast, ATM PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for BRCA1, 27% for BRCA2, and 13% for CHEK2 PV carriers with breast cancer and 35% for PALB2 PV carriers with ER-negative breast cancer. The 10-year cumulative incidence of CBC among postmenopausal PV carriers was 12% for BRCA1, 9% for BRCA2, and 4% for CHEK2. CONCLUSION Women diagnosed with breast cancer and known to carry germline PVs in BRCA1, BRCA2, CHEK2, or PALB2 are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.
The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
Metcalfe, Kelly , McCuaig, Jeanna , Eisen, Andrea , Elser, Christine , Senter, Leigha , Møller, Pål , Bordeleau, Louise , Velsher, Lea, Zakalik, Dana , Olopade, Olufunmilayo I. , Cullinane, Carey A., Sun, Ping , Narod, Steven A. , Metcalfe, Kelly A , Olopade, Olufunmilayo I , Kotsopoulos, Joanne , Narod, Steven A , Senter, Leigha , Eisen, Andrea , Bordeleau, Louise , Gronwald, Jacek , Tung, Nadine , Foulkes, William D. , Neuhausen, Susan L. , Fruscio, Robert , Eng, Charis , Pal, Tuya , Couch, Fergus J. , Kotsopoulos, Joanne , Lubiński, Jan

Mayo Clinic

Cancer | December 26, 2022 | Volume: 129 | Issue: 6 | Pages: 901-907

10.1002/cncr.34615 | PMID 36571512 Get It

AbstractBackgroundThe purpose of this study was to estimate the cumulative risks of all cancers in women from 50 to 75 years of age with a BRCA1 or BRCA2 pathogenic variant.MethodsParticipants were women with BRCA1 or BRCA2 pathogenic variants from 85 centers in 16 countries. Women were eligible if they had no cancer before the age of 50 years. Participants completed a baseline questionnaire and follow‐up questionnaires every 2 years. Women were followed from age 50 until a diagnosis of cancer, death, age 75, or last follow‐up. The risk of all cancers combined from age 50 to 75 was estimated using the Kaplan–Meier method.ResultsThere were 2211 women included (1470 BRCA1 and 742 BRCA2). There were 379 cancers diagnosed in the cohort between 50 and 75 years. The actuarial risk of any cancer from age 50 to 75 was 49% for BRCA1 and 43% for BRCA2. Breast (n = 186) and ovarian (n = 45) were the most frequent cancers observed. For women who had both risk‐reducing mastectomy and bilateral salpingo‐oophorectomy before age 50, the risk of developing any cancer between age 50 and 75 was 9%.ConclusionWomen with a BRCA1 or BRCA2 pathogenic variant have a high risk of cancer between the ages of 50 and 75 years and should be counselled appropriately.
Abstract A003: Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes
Couch, Ronan E. , LaDuca, Holly , Goldgar, David E. , Pesaran, Tina , Dolinsky, Jill S. , Teras, Lauren R., Patel, Alpa V. , Ruddy, Kathryn J. , Vachon, Celine M. , Yao, Song, Huang, Huaizhi , Yadav, Siddhartha , Polley, Eric C. , Boddicker, Nicholas , Na, Jie , Gnanaolivu, Rohan , Hart, Steven N. , Palmer, Julie R. , Teras, Lauren R. , Olson, Janet E. , Vachon, Celine M. , Kraft, Peter , Yao, Song , Trentham‐Dietz, Amy , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Domchek, Susan M. , Couch, Fergus J. , Hu, Chunling

Mayo Clinic

Cancer Prevention Research | December 1, 2022 | Volume: 15 | Issue: 12_Supplement_1 | Pages: A003-A003

10.1158/1940-6215.dcis22-a003 Get It

Abstract Introduction: The relationship between germline pathogenic variants (PVs) in cancer predisposition genes and ductal carcinoma in situ (DCIS) is not well established. The objective of this study is to determine the risks of DCIS and contralateral breast cancer among women with DCIS associated with germline PVs in cancer predisposition genes. Methods: Associations between pathogenic variants in 11 cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MSH6, PALB2, RAD51C, and RAD51D) and DCIS were determined in case control analyses of a population-based cohort of 3876 women with DCIS and age-matched unaffected women, and in a clinical cohort of 9887 DCIS cases undergoing clinical genetic testing at Ambry Genetics and unaffected reference controls. The incidence of contralateral breast cancer risk in BRCA1, BRCA2, and PALB2 PV carriers with DCIS was also evaluated in a time-to-event analysis. Results: The mean age at diagnosis of DCIS was 50 years in the clinical testing cohort and 59 years in the population-based cohort. The frequency of PVs in 11 predisposition genes among DCIS cases was 6.9% in the clinical testing cohort and 4.9% in the population-based cohort. PVs in ATM, BRCA1, BRCA2, CHEK2, MSH6, PALB2, and RAD51D were associated with significantly increased risks (Odds Ratio (OR) >2) of DCIS in the clinical testing cohort whereas only PVs in BRCA1, CHEK2, PALB2, and ATM were associated with significantly increased risks of DCIS in the population-based cohort. The cumulative incidence of contralateral breast cancer among BRCA1, BRCA2, and PALB2 PV carriers with DCIS was 11% in 5-years and 20% in 15-years. Conclusions: This study provides new insights into PVs that predispose to DCIS. In addition, it establishes an increased risk of contralateral breast cancer risk among women with DCIS who are carriers of PVs in BRCA1, BRCA2, or PALB2. These findings will guide surveillance and risk reducing strategies in germline PV carriers with DCIS. Citation Format: Huaizhi Huang, Ronan E. Couch, Holly LaDuca, Siddhartha Yadav, Eric C. Polley, Nicholas J. Boddicker, Jie Na, Rohan D. Gnanaolivu, David E. Goldgar, Tina Pesaran, Steven N. Hart, Jill S. Dolinsky, Julie R. Palmer, Lauren Teras, Alpa V. Patel, Kathryn J. Ruddy, Janet E. Olson, Celine M. Vachon, Peter Kraft, Song Yao, Amy Trentham-Dietz, Katherine L. Nathanson, Jeffrey N. Weitzel, Susan M. Domchek, Fergus J. Couch, Chunling Hu. Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr A003.
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
Belhadj, Sami , Khurram, Aliya , Bandlamudi, Chaitanya , Palou-Márquez, Guillermo , Steinsnyder, Zoe , Wildman, Temima , Catchings, Amanda , Kemel, Yelena , Mukherjee, Semanti , Fesko, Benjamin , Mehine, Miika , Dandiker, Sita , Izhar, Aalin , Nathanson, Katherine L. , Brower, Jamie , Walsh, Michael F. , Topka, Sabine , Offit, Kenneth , Ravichandran, Vignesh , Steinsnyder, Zoe , Wildman, Temima , Catchings, Amanda , Kemel, Yelena , Mukherjee, Semanti , Fesko, Benjamin , Arora, Kanika , Mehine, Miika , Dandiker, Sita , Izhar, Aalin , Petrini, John , Domchek, Susan M , Nathanson, Katherine L , Brower, Jamie , Couch, Fergus J. , Stadler, Zsofia , Robson, Mark , Walsh, Michael , Joseph, Vijai , Berger, Michael , Supek, Fran , Karam, Rachid , Topka, Sabine , Offit, Kenneth , Ravichandran, Vignesh , Domchek, Susan M. , Couch, Fergus J. , Robson, Mark E. , Vijai, Joseph , Karam, Rachid

Mayo Clinic

Clinical Cancer Research | November 8, 2022 | Volume: 29 | Issue: 2 | Pages: 422-431

10.1158/1078-0432.ccr-22-1703 | PMID 36346689 Get It

Abstract Purpose: To explore the role of NBN as a pan-cancer susceptibility gene. Experimental Design: Matched germline and somatic DNA samples from 34,046 patients were sequenced using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and presumed pathogenic germline variants (PGV) identified. Allele-specific and gene-centered analysis of enrichment was conducted and a validation cohort of 26,407 pan-cancer patients was analyzed. Functional studies utilized cellular models with analysis of protein expression, MRN complex formation/localization, and viability assessment following treatment with γ-irradiation. Results: We identified 83 carriers of 32 NBN PGVs (0.25% of the studied series), 40% of which (33/83) carried the Slavic founder p.K219fs. The frequency of PGVs varied across cancer types. Patients harboring NBN PGVs demonstrated increased loss of the wild-type allele in their tumors [OR = 2.7; confidence interval (CI): 1.4–5.5; P = 0.0024; pan-cancer], including lung and pancreatic tumors compared with breast and colorectal cancers. p.K219fs was enriched across all tumor types (OR = 2.22; CI: 1.3–3.6; P = 0.0018). Gene-centered analysis revealed enrichment of PGVs in cases compared with controls in the European population (OR = 1.9; CI: 1.3–2.7; P = 0.0004), a finding confirmed in the replication cohort (OR = 1.8; CI: 1.2–2.6; P = 0.003). Two novel truncating variants, p.L19* and p.N71fs, produced a 45 kDa fragment generated by alternative translation initiation that maintained binding to MRE11. Cells expressing these fragments showed higher sensitivity to γ-irradiation and lower levels of radiation-induced KAP1 phosphorylation. Conclusions: Burden analyses, biallelic inactivation, and functional evidence support the role of NBN as contributing to a broad cancer spectrum. Further studies in large pan-cancer series and the assessment of epistatic and environmental interactions are warranted to further define these associations.
Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers
McKenna, Danielle , Sanchez, Pauleen, Powers, Jacquelyn , Brower, Jamie , Wang, Louise , Mueller, Rebecca , Symecko, Heather , Hamilton, Jada G. , Wildman, Temima , Offit, Kenneth , McKenna, Danielle B , Katona, Bryson W , Domchek, Susan M. , Couch, Fergus J. , Garber, Judy E. , Robson, Mark E.

Mayo Clinic

Journal of Genetic Counseling | October 17, 2022 | Volume: 32 | Issue: 2 | Pages: 342-350

10.1002/jgc4.1641 | PMID 36245263 Get It

AbstractGermline genetic testing for inherited cancer risk is increasingly being performed with multigene panel testing with MUTYH often included on colorectal cancer‐ and polyposis‐focused panels, as well as on broader pan‐cancer panels. With up to 1%–2% of the general population being monoallelic MUTYH carriers, pathogenic/likely pathogenic (P/LP) variants in MUTYH are one of the most common findings on multigene cancer panels. However, little is known about patient experience and understanding of monoallelic MUTYH P/LP variants, nor whether such findings influence medical management recommendations and familial communication, which this study aims to better understand. Monoallelic P/LP MUTYH carriers were recruited from the Prospective Registry of Multiplex Testing (PROMPT) and completed a cross‐sectional self‐report survey on sociodemographic characteristics, medical and family history, experiences with MUTYH genetic testing, genetics and MUTYH knowledge, perceived cancer risk, and familial communication. Of 115 eligible PROMPT participants, 49 (43%) completed the survey who were primarily female (94%), white (96%), had a history of cancer (61%), and a median age of 51.4 years. Most participants (61%) reported satisfaction with how their healthcare provider managed their genetic test result and care, and 65% of survey participants reported their provider recommended colonoscopy based on their genetic test results. Participants' responses also reflected variable levels of knowledge regarding cancer risks and screening recommendations for MUTYH carriers. The majority (98%) of participants shared their genetic test results with at least some of their relatives; however, only 13% of eligible relatives reportedly underwent cascade testing. Taken together, this study provides needed insight into the overall experiences of monoallelic MUTYH carriers and highlights numerous areas for improvement in clinician education, communication, and management of these individuals.
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration
Lohse, Christine M. , Castillo, Anna , Tosakulwong, Nirubol , Lesnick, Timothy G. , Petersen, Ronald C. , Ruddy, Kathryn J. , Kantarci, Kejal , Kara, Firat , Castillo, Anna M, Ruddy, Kathryn J , Mielke, Michelle M , Kantarci, Kejal , Castillo, Anna M , Jack, Clifford R. , Olson, Janet E. , Couch, Fergus J. , Mielke, Michelle M.

Mayo Clinic

Cancer Medicine | August 30, 2022 | Volume: 12 | Issue: 3 | Pages: 2805-2817

10.1002/cam4.5175 | PMID 36040183 Get It

Abstract The aim of this cross‐sectional study was to examine whether a history of selective estrogen receptor modifiers (SERMs), tamoxifen and raloxifene, use was associated with cognitive performance, odds of mild cognitive impairment (MCI), or magnetic resonance imaging (MRI) markers of neurodegeneration associated with Alzheimer's disease. We included women with prior history of breast cancer or no prior history of any cancer at enrollment in the Mayo Clinic Study of Aging (MCSA). This information was abstracted using the Rochester Epidemiology Project medical‐linkage system. Logistic regression was used to examine associations of SERMs with odds of MCI. Linear regression models were used to examine associations of SERMs with cognitive z‐scores (Memory, Executive Function, Language, Visuospatial Skills, Global Cognition), and MRI markers. Among 2840 women aged 50 and older in the MCSA, 151 had a history of breast cancer, and 42 (28%) of these had a history of tamoxifen treatment. A total of 2235 women had no prior history of any cancer, and 76 (3%) of these had a history of raloxifene use. No significant associations between tamoxifen use and cognition, or odds of MCI were observed among women with a history of breast cancer after adjusting for confounders. Similarly, raloxifene use was not significantly associated with cognition, or odds of MCI in women without a history of cancer after adjusting for confounders. We did not find significant associations between the use of either SERM and MRI markers. Use of tamoxifen or raloxifene was not significantly associated with cognition in postmenopausal women.
Factors Associated With Physical Activity Levels in Patients With Breast Cancer
Marell, Paulina S. , Herrmann, Joerg , D’Andre, Stacy D, Cheville, Andrea , Barksdale, Toure, Loprinzi, Charles L. , Ruddy, Kathryn J. , Cheville, Andrea L , Ruddy, Kathryn J , Vierkant, Robert A. , Olson, Janet E. , Larson, Nicole , LeBrasseur, Nathan K. , Barksdale, Touré, Couch, Fergus J.

Mayo Clinic

The Oncologist | August 10, 2022 | Volume: 27 | Issue: 10 | Pages: e811-e814

10.1093/oncolo/oyac159 | PMID 35946834 Get It

Abstract Physical activity (PA) is associated with improvement in breast cancer treatment-related symptoms and survival, yet most breast cancer survivors do not meet national PA guidelines. This study aimed to identify characteristics of participants that were associated with an increased likelihood of meeting PA guidelines. Adults with breast cancer seen at Mayo Clinic (Rochester, MN) were surveyed regarding their PA participation, and those who self-reported at least 150 minutes of moderate and/or strenuous aerobic PA weekly on average were considered to be “meeting guidelines”. Three thousand participants returned PA data. Younger age, completion of the survey 7-12 years after diagnosis, absence of recurrence, no bilateral mastectomy, absence of metastatic disease, and lower BMI at the time of survey completion were associated with PA participation (P < .05 in univariate and multivariate analyses). Findings were similar when a threshold of 90 minutes was applied. These results may inform the development of targeted PA-facilitating interventions.
Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study
Chen, Fei , Park, Sungshim L. , Wan, Peggy , Hart, Steven N. , Yadav, Siddhartha , Couch, Fergus J. , Haiman, Christopher A. , Chen, Chen , Hart, Steven N , Hu, Chunling , Yadav, Siddhartha , Couch, Fergus J. , Haiman, Christopher A , Chen, C , Chen, Fei , Wilkens, Lynne R. , Hu, Chunling , Conti, David V. , Smith, Adam J. de

Mayo Clinic

Cancer Research | July 14, 2022 | Volume: 82 | Issue: 18 | Pages: 3201-3208

10.1158/0008-5472.can-21-4461 | PMID 35834270 Get It

Abstract Women who have had breast cancer in the past are at increased risk of developing a second primary cancer (SPC), including second primary breast cancer (SPBC) or a second primary non-breast cancer (SPNBC). In the Multiethnic Cohort (MEC) Study, we conducted a prospective cohort analysis in 3,223 female breast cancer survivors from five racial/ethnic populations (White, African American, Japanese American, Latino, and Native Hawaiian) to assess the association of rare pathogenic variants (PV) in 37 known cancer predisposition genes with risk of SPC. A total of 719 (22.3%) women developed SPC, of which, 323 (10.0%) were SPBC. Germline PVs in BRCA1 (HR, 2.28; 95% CI, 1.11–4.65) and ERCC2 (HR, 3.51; 95% CI, 1.29–9.54) were significantly enriched in women with SPC. In the subtype analysis for SPBC, a significant association of ERCC2 PVs (HR, 5.09; 95% CI, 1.58–16.4) and a suggestive association of BRCA2 PVs (HR, 2.24; 95% CI, 0.91–5.55) were observed. There was also a higher risk of SPNBC in carriers of BRCA1 PVs (HR, 2.98; 95% CI, 1.21–7.36). These results provide evidence that germline PVs in BRCA1, BRCA2, and ERCC2 contribute to the development of SPC in breast cancer survivors. These findings also suggest that compromised DNA repair mechanisms could be a predisposition factor for SPC in patients with breast cancer, supporting the need for closer monitoring of SPC in women carrying PVs in these genes. Significance: This multiethnic study links germline pathogenic variants in BRCA1, BRCA2, and ERCC2 to the development of second primary cancer in breast cancer survivors, providing biological insights and biomarkers to guide patient monitoring.